thiazoles has been researched along with pf 00299804 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Knecht, R; Kurzweg, T; Laban, S; Möckelmann, N | 1 |
Ahn, YO; Heo, DS; Keam, B; Kim, DW; Kim, S; Kim, TM; Lee, SH | 1 |
1 review(s) available for thiazoles and pf 00299804
Article | Year |
---|---|
Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzodioxoles; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Dasatinib; ErbB Receptors; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Indoles; Neoplasm Recurrence, Local; Palliative Care; Pyrimidines; Pyrroles; Quinazolines; Quinazolinones; Salvage Therapy; Squamous Cell Carcinoma of Head and Neck; Sunitinib; Thiazoles | 2012 |
1 other study(ies) available for thiazoles and pf 00299804
Article | Year |
---|---|
In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Drug Synergism; Head and Neck Neoplasms; Humans; Phosphoinositide-3 Kinase Inhibitors; Quinazolinones; Thiazoles | 2015 |